XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2

Segments (Tables)

6 Months Ended

Jun. 30, 2020

Summary of Segment Profit

a. Segment information:

		Three months ended June 30,
		2020
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,047			$	1,001			$	488
Gross profit			1,090				548				247
R&D expenses			154				65				19
S&M expenses			254				188				105
G&A expenses			110				52				29
Other (income) expenses			(2	)			(1	)			(2	)
Segment profit		$	573			$	244			$	97

		Three months ended June 30,
		2019
		North America				Europe				International Markets*
		(U.S. $ in millions)
Revenues		$	2,071			$	1,183			$	582
Gross profit			1,067				674				312
R&D expenses			175				70				24
S&M expenses			269				216				119
G&A expenses			117				70				34
Other (income) expenses			2				1				(1	)
Segment profit		$	504			$	316			$	136

		Six months ended June 30,
		2020
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	4,129			$	2,404			$	1,053
Gross profit			2,152				1,371				552
R&D expenses			300				120				34
S&M expenses			505				390				211
G&A expenses			228				118				63
Other (income) expenses			(4	)			(2	)			(8	)
Segment profit		$	1,123			$	746			$	253

		Six months ended June 30,
		2019
		North America				Europe				International Markets*
		(U.S. $ in millions)
Revenues		$	4,118			$	2,448			$	1,103
Gross profit			2,107				1,404				582
R&D expenses			340				136				46
S&M expenses			537				431				234
G&A expenses			230				119				70
Other (income) expenses			(2	)			(1	)			(1	)
Segment profit		$	1,001			$	719			$	233

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.

Schedule Of Consolidated Income Before Income Tax

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and six months ended June 30, 2020 and 2019:

		Three months ended								Six months ended
		June 30,								June 30,
		2020				2019				2020				2019
		(U.S. $ in millions)								(U.S. $ in millions)
North America profit		$	573			$	504			$	1,123			$	1,001
Europe profit			244				316				746				719
International Markets profit			97				136				253				233
Total reportable segments profit			914				956				2,121				1,954
Profit of other activities			66				55				102				76
Total segments profit			979				1,011				2,223				2,029
Amounts not allocated to segments:
Amortization			249				285				507				568
Other assets impairments, restructuring and other items			381				101				502				103
Intangible asset impairments			120				561				768				1,030
Legal settlements and loss contingencies			13				646				(12	)			703
Other unallocated amounts			44				62				93				136
Consolidated operating income (loss)			173				(644	)			364				(510	)
Financial expenses, net			223				206				448				425
Consolidated income (loss) before income taxes		$	(51	)		$	(850	)		$	(84	)		$	(934	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for the three and six months ended June 30, 2020 and 2019:

North America		Three months ended June 30,
		2020				2019
		(U.S. $ in millions)
Generic products		$	923			$	946
AJOVY			34				23
AUSTEDO			161				96
BENDEKA/TREANDA			103				125
COPAXONE			238				274
ProAir*			66				65
QVAR			51				60
Anda			374				351
Other			96				131
Total		$	2,047			$	2,071

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

North America		Six months ended June 30,
		2020				2019
		(U.S. $ in millions)
Generic products		$	1,875			$	1,913
AJOVY			63				43
AUSTEDO			283				171
BENDEKA/TREANDA			208				247
COPAXONE			435				482
ProAir*			125				123
QVAR			97				124
Anda			800				729
Other			242				286
Total		$	4,129			$	4,118

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

Europe		Three months ended June 30,
		2020				2019
		(U.S. $ in millions)
Generic products		$	737			$	844
COPAXONE			84				107
Respiratory products			80				89
AJOVY			5				1
Other			95				142
Total		$	1,001			$	1,183

Europe		Six months ended June 30,
		2020				2019
		(U.S. $ in millions)
Generic products		$	1,769			$	1,763
COPAXONE			193				221
Respiratory products			186				181
AJOVY			9				1
Other			246				282
Total		$	2,404			$	2,448

International Markets		Three months ended June 30,
		2020				2019*
		(U.S. $ in millions)
Generic products		$	426			$	489
COPAXONE			12				13
Other			50				80
Total		$	488			$	582

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.

International Markets		Six months ended June 30,
		2020				2019*
		(U.S. $ in millions)
Generic products		$	875			$	930
COPAXONE			23				27
Other			154				147
Total		$	1,053			$	1,103

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c for additional information.

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration